

Hege Sagstuen Haugnes

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7091399/publications.pdf>

Version: 2024-02-01

27
papers

296
citations

933447

10
h-index

940533

16
g-index

28
all docs

28
docs citations

28
times ranked

407
citing authors

#	ARTICLE	IF	CITATIONS
1	Unilateral or Bilateral Retroperitoneal Lymph Node Dissection in Nonseminoma Patients with Postchemotherapy Residual Tumour? Results from RETROP, a Population-based Mapping Study by the Swedish Norwegian Testicular Cancer Group. <i>European Urology Oncology</i> , 2022, 5, 235-243.	5.4	11
2	Expression of miR-24-1-5p in Tumor Tissue Influences Prostate Cancer Recurrence: The PROCA-life Study. <i>Cancers</i> , 2022, 14, 1142.	3.7	4
3	Mortality and Second Cancer Incidence After Treatment for Testicular Cancer: Psychosocial Health and Lifestyle Are Modifiable Prognostic Factors. <i>Journal of Clinical Oncology</i> , 2022, 40, 2588-2599.	1.6	7
4	Testicular Cancer in the Cisplatin Era: Causes of Death and Mortality Rates in a Population-Based Cohort. <i>Journal of Clinical Oncology</i> , 2021, 39, 3561-3573.	1.6	46
5	Thromboembolic Events During Treatment with Cisplatin-based Chemotherapy in Metastatic Testicular Germ-cell Cancer 2000-2014: A Population-based Cohort Study. <i>European Urology Open Science</i> , 2021, 32, 19-27.	0.4	10
6	Surgical Complications in Postchemotherapy Retroperitoneal Lymph Node Dissection for Nonseminoma Germ Cell Tumour: A Population-based Study from the Swedish Norwegian Testicular Cancer Group. <i>European Urology Oncology</i> , 2020, 3, 382-389.	5.4	28
7	Inflammatory serum markers and risk and severity of prostate cancer: The PROCA-life study. <i>International Journal of Cancer</i> , 2020, 147, 84-92.	5.1	26
8	Sexual function in long-term male lymphoma survivors after high-dose therapy with autologous stem-cell transplantation. <i>Bone Marrow Transplantation</i> , 2020, 55, 891-905.	2.4	12
9	PD19-06 LOCATION AND HISTOLOGY OF RETROPERITONEAL METASTASES IN POST-CHEMOTHERAPY RETROPERITONEAL LYMPH NODE DISSECTION FOR NON-SEMINOMA GERM CELL TUMOUR. <i>Journal of Urology</i> , 2020, 203, e384.	0.4	0
10	Cancer therapy and risk of congenital malformations in children fathered by men treated for testicular germ-cell cancer: A nationwide register study. <i>PLoS Medicine</i> , 2019, 16, e1002816.	8.4	17
11	Lifestyle behavior among lymphoma survivors after high-dose therapy with autologous hematopoietic stem cell transplantation, assessed by patient-reported outcomes. <i>Acta Oncologica</i> , 2019, 58, 690-699.	1.8	11
12	Questioning the Value of Fluorodeoxyglucose Positron Emission Tomography for Residual Lesions After Chemotherapy for Metastatic Seminoma: Results of an International Global Germ Cell Cancer Group Registry. <i>Journal of Clinical Oncology</i> , 2018, 36, 3381-3387.	1.6	49
13	Long-term platinum (Pt) change and its associations with cisplatin-related late effects in testicular cancer survivors (TCSs).. <i>Journal of Clinical Oncology</i> , 2018, 36, e22067-e22067.	1.6	0
14	FDG PET scan (PET) positive residual lesions after chemotherapy (chemo) for metastatic seminoma: Results of an International Global Germ Cell Cancer Group (G3) registry.. <i>Journal of Clinical Oncology</i> , 2017, 35, 4521-4521.	1.6	11
15	Thromboembolic events after high-intensity training during cisplatin-based chemotherapy for testicular cancer.. <i>Journal of Clinical Oncology</i> , 2017, 35, 4551-4551.	1.6	2
16	Audiograms and hearing loss before and after cisplatin-based chemotherapy (CBCT) in testicular cancer survivors (TCS).. <i>Journal of Clinical Oncology</i> , 2017, 35, e16047-e16047.	1.6	0
17	The ABC-study: A randomized phase III study comparing one course of adjuvant bleomycin, etoposide, and cisplatin (BEP) and one course of carboplatin AUC7 in clinical stage I seminomatous testicular cancer.. <i>Journal of Clinical Oncology</i> , 2017, 35, TPS4593-TPS4593.	1.6	2
18	Cardiovascular risk and the impact of self-reported physical activity in long-term testicular cancer survivors: A longitudinal study.. <i>Journal of Clinical Oncology</i> , 2016, 34, e16048-e16048.	1.6	1

#	ARTICLE	IF	CITATIONS
19	Bilateral testicular germ cell tumors in patients treated for clinical stage I non-seminoma within two risk-adapted SWENOTECA protocols. <i>Acta Oncologica</i> , 2015, 54, 493-499.	1.8	13
20	Management of clinical stage I seminomatous testicular cancer: A report from SWENOTECA.. <i>Journal of Clinical Oncology</i> , 2014, 32, 4508-4508.	1.6	9
21	Fatigue in relation to treatment and gonadal function in a population-based sample of 796 testicular cancer survivors 12 and 19 years after treatment.. <i>Journal of Clinical Oncology</i> , 2014, 32, 4564-4564.	1.6	2
22	Impact of long-term serum platinum on neuro- and ototoxicity, cardiovascular disease, and hypogonadism in testicular cancer survivors.. <i>Journal of Clinical Oncology</i> , 2014, 32, 4518-4518.	1.6	1
23	One course of adjuvant BEP in clinical stage I, nonseminoma: Mature and expanded results from the SWENOTECA group.. <i>Journal of Clinical Oncology</i> , 2013, 31, 4553-4553.	1.6	3
24	Testosterone (T), luteinizing hormone (LH), and follicle stimulating hormone (FSH) levels in testicular cancer survivors (TCSs) 11 and 19 years after orchiectomy.. <i>Journal of Clinical Oncology</i> , 2013, 31, 4562-4562.	1.6	11
25	Bilateral testicular cancer within two prospective, population-based SWENOTECA protocols in clinical stage I nonseminoma.. <i>Journal of Clinical Oncology</i> , 2012, 30, 4508-4508.	1.6	11
26	Longitudinal serum testosterone levels (T) in long-term testicular cancer survivors (TCSs) in relation to testicular cancer (TC) treatment, aging, and TC diagnosis itself.. <i>Journal of Clinical Oncology</i> , 2012, 30, 4637-4637.	1.6	0
27	A controlled study of risk factors for disease and current problems in long-term testicular cancer survivors. <i>Journal of Cancer Survivorship</i> , 2010, 4, 256-265.	2.9	8